Expert Support for Development and Characterization at Every Phase of the Project Cycle
High-resolution mass spectrometry is a powerful tool used at KBI Biopharma for analytical strategies concerning complex samples. In support of biotherapeutics across the board, KBI's Mass Spectrometry Core Facility has championed the characterization and management of proteins, active pharmaceutical ingredients (APIs), and impurities through identification, characterization, assessment, and quantitation. At KBI, we are true partners working hand-in-hand with clients to conquer complexities and develop lasting solutions to the analytical challenges that come with the development of biologics.
- High Selectivity
- High Sensitivity
- High Specificity
- High Resolution
- Backed by Decades of Experience
.png?width=175&height=175&name=MicrosoftTeams-image%20(69).png)
Q&A with KBI's Mass Spectrometry Team
We recently sat down with Michael J. Nold, Ph.D., Senior Director of KBI’s Mass Spectrometry Core Facility in Durham, North Carolina, to discuss how advanced Mass Spectrometry plays a significant analytical role in the characterization and quantitation of APIs and impurities in complex biotherapeutics.
.png?width=175&height=175&name=MicrosoftTeams-image%20(70).png)
Using Advanced Mass Spectrometry for Characterization and Quantitation of APIs and Impurities in Complex Biotherapeutics
Advanced analytical capabilities, including mass spectrometry, are critical for the characterization of active pharmaceutical ingredients (APIs) and managing a diverse population of impurities. This allows for effective mitigation of safety risks and ensures product quality.
